TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1351804

Group type: EXPERIMENTAL
Intervention: 75 mg tramadol hydrochloride
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 150 mg tramadol hydrochloride
Number of subjects: 161

Group type: COMPARATOR
Intervention: Acetaminophen plus propoxyphene napsylate (650 mg + 100 mg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 31398932

Group type: EXPERIMENTAL
Intervention: Intensive intervention based on diet and physical activity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard intervention (control)
Number of subjects: 20
Study: 30246748

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (CHX) gel
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1% metronidazole gel
Number of subjects: 34
Study: 26403199

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 5107

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5107
Study: 24113254

Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate 250 mg weekly
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: COMPARATOR
Intervention: Omega-3 supplementation
Number of subjects: 315
Study: 22857778

Group type: EXPERIMENTAL
Intervention: Real acupuncture with optimistic communication
Number of subjects: 311

Group type: COMPARATOR
Intervention: Sham acupuncture with neutral expectations
Number of subjects: 311
Study: 20145342

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) + statin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete adherence
Number of subjects: 0
Study: 18357861

Group type: EXPERIMENTAL
Intervention: MPC algorithm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 20
Study: 16236835

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg/d
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/d
Number of subjects: 863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FSC), 100/50 microg bid for 4 weeks
Number of subjects: 863
Study: 12109769

Group type: EXPERIMENTAL
Intervention: Strategic moves available in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Failure to capitalize on visual hints in Experiment 2
Number of subjects: 0
Study: 10534607

Group type: COMPARATOR
Intervention: Nalbuphine 5 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nalbuphine 20 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nalbuphine 10 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg, 10 mg, 20 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 7793652

Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg oral)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 21
Study: 2108816

Group type: EXPERIMENTAL
Intervention: CAPM (cyclophosphamide, Adriamycin, cisplatin, mitomycin C)
Number of subjects: 136

Group type: COMPARATOR
Intervention: MCT (mitomycin C, cytosine arabinoside, tegafur)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CAPM
Number of subjects: 136

Group type: COMPARATOR
Intervention: MCT
Number of subjects: 136
Study: 6158404

Group type: EXPERIMENTAL
Intervention: Selective auditory attention to high frequency tones
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Selective auditory attention to low frequency tones
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unattended shorter tones
Number of subjects: 12
Study: 31427870

Group type: EXPERIMENTAL
Intervention: 4-min core muscle exercise with inspiratory loaded breathing after 11-min passive recovery
Number of subjects: 9

Group type: COMPARATOR
Intervention: 15-min passive recovery
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Anterior thigh muscle perfusion assessed by near-infrared spectroscopy following the re-warm-up exercises
Number of subjects: 9
Study: 28829934

Group type: EXPERIMENTAL
Intervention: TBS (tribochemical silica coating via air‐abrasion with 30‐μm silica‐coated alumina particles)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NANO (silica nanofilm deposition via magnetron sputtering)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GHF1 (glaze application + HF for 1 minute)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GHF15 (glaze application + HF for 15 minutes)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GHF5 (glaze application + HF for 5 minutes)
Number of subjects: 100
Study: 25742472

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CB)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Capecitabine alone (C)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab plus mitomycin C (CBM)
Number of subjects: 280
Study: 23880010

Group type: EXPERIMENTAL
Intervention: Non-laboratory-based CVD risk score
Number of subjects: 14772
Study: 21849186

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 5379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5379
Study: 19552227

Group type: EXPERIMENTAL
Intervention: Sensory-adapted dental environment (SADE)
Number of subjects: 16
Study: 17343309

Group type: EXPERIMENTAL
Intervention: Therapeutic intervention (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublining CD68+ macrophages
Number of subjects: 0
Study: 15541162

Group type: EXPERIMENTAL
Intervention: 5.0% NaF varnish
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.05% NaF rinse
Number of subjects: 16
Study: 11295651

Group type: EXPERIMENTAL
Intervention: Self-reported sensitivities to environmental factors
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Self-reported sensitivities to animal exposure
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Environmental modification of homes
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Exposure to parental cigarette smoking
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Exposure to house dust
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Exposure to damp and musty areas
Number of subjects: 1041
Study: 9560064

Group type: EXPERIMENTAL
Intervention: Thioridazine 75 mg (TDZ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thioridazine (0, 25, 50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thioridazine (75 mg)
Number of subjects: 12
Study: 7889948

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 139

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 139
Study: 17171865

Group type: EXPERIMENTAL
Intervention: EMLA applied at least 90 minutes prior to cannulation
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: EMLA applied 60 minutes prior to cannulation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lidocaine 2% infiltration performed immediately prior to the procedure
Number of subjects: 3
Study: 30614275

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 13287

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 13287
Study: 27720981

Group type: EXPERIMENTAL
Intervention: Alkalinised 0.75% ropivacaine-2% mepivacaine solution (pH 7.0)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard local anaesthetic solution (0.75% ropivacaine 5ml and 2% mepivacaine 5ml, pH 5.9)
Number of subjects: 40
Study: 26360446

Group type: EXPERIMENTAL
Intervention: REFOCUS intervention (usual treatment plus REFOCUS)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (usual treatment alone)
Number of subjects: 403
Study: 23833853

Group type: EXPERIMENTAL
Intervention: Proseal LMA (PLMA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Classic LMA (cLMA)
Number of subjects: 200
Study: 21875240

Group type: EXPERIMENTAL
Intervention: Group Psychodynamic‐Interpersonal Psychotherapy (GPIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 0
Study: 19286579

Group type: EXPERIMENTAL
Intervention: PNS+tDCS
Number of subjects: 9
Study: 17886373

Group type: EXPERIMENTAL
Intervention: Affinoleukin added to regular treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Regular treatment alone
Number of subjects: 161
Study: 15884317

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total-etching adhesive
Number of subjects: 80

Group type: COMPARATOR
Intervention: Caries-affected dentin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intact dentin
Number of subjects: 80
Study: 11206236

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI), 400 microg once daily in the morning (AM)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg once daily in the evening (PM)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg twice daily
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 9648990

Group type: EXPERIMENTAL
Intervention: Active Crohn's disease
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Inactive disease
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Crohn's disease with fistulas
Number of subjects: 55
Study: 8010269

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patients with microadenomas
Number of subjects: 66
Study: 2700641

Group type: EXPERIMENTAL
Intervention: Toothbrush A (4.5 bristles per mm2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Toothbrush B (8.3 bristles per mm2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Toothbrush C (11.8 bristles per mm2)
Number of subjects: 90
Study: 786353

Group type: EXPERIMENTAL
Intervention: acebutolol (Sectral) 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: practolol (Eraldin) 300 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31981921

Group type: EXPERIMENTAL
Intervention: Single dose of intravenous co-amoxiclav
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 60
Study: 29224236

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screen-detected cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cases detected outside screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary treatment
Number of subjects: 0
Study: 28673611

Group type: EXPERIMENTAL
Intervention: Curved-walking training (CWT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control exercise (CE)
Number of subjects: 24
Study: 26657844

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI) for males aged 75 years and above
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual post-discharge care (control)
Number of subjects: 0
Study: 23370069

Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM) collaborative care intervention (cognitive‐behavioral therapy and/or medication)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Opioid medications in patients with comorbid major depression
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Opioid medications in patients with pain
Number of subjects: 1004
Study: 21514147

Group type: EXPERIMENTAL
Intervention: docetaxel/oxaliplatin (75 mg/m² on day 1 and 70 mg/m² on day 2 every 3 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: docetaxel (75 mg/m² on day 1 every 3 weeks)
Number of subjects: 50
Study: 18451314

Group type: EXPERIMENTAL
Intervention: tNSAIDs, glucocorticoids, or coxibs (any inhibitor) with NT-proBNP > or = 100 ng/L
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Coxibs (alone or with tNSAIDs or glucocorticoids) with NT-proBNP > or = 100 ng/L
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Two or more antiinflammatory drugs with NT-proBNP > or = 100 ng/L
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: NT-proBNP <100 ng/L across all treatment groups
Number of subjects: 433
Study: 17040253

Group type: COMPARATOR
Intervention: ICD therapy in male patients
Number of subjects: 5

Group type: COMPARATOR
Intervention: ICD therapy in female patients
Number of subjects: 5

Group type: COMPARATOR
Intervention: ICD therapy in male patients (excluding COMPANION trial)
Number of subjects: 5

Group type: COMPARATOR
Intervention: ICD therapy in female patients (excluding COMPANION trial)
Number of subjects: 5
Study: 12943944

Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants (clomipramine mean dose 145 mg and fluoxetine mean dose 27 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenergic antidepressants (desipramine mean dose 200 mg and nortriptyline mean dose 100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noradrenergic antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serotonergic antidepressants
Number of subjects: 0
Study: 9559790

Group type: EXPERIMENTAL
Intervention: Didanosine exposure
Number of subjects: 82
Study: 8582392

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 23
Study: 2676559

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Felodipine (not specified)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine (not specified)
Number of subjects: 16
Study: 756039

Group type: EXPERIMENTAL
Intervention: High sodium dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard, hyponatric dialysis
Number of subjects: 0
Study: 30586701

Group type: EXPERIMENTAL
Intervention: MitraClip procedure
Number of subjects: 616
Study: 28457231

Group type: EXPERIMENTAL
Intervention: Disease management program delivered by multi-disciplinary teams
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Usual care by primary care practitioners and consultant cardiologists
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1360
Study: 24971677

Group type: EXPERIMENTAL
Intervention: EX: exercise 5 days/week for 40 min/session at moderate intensity
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: EX‐rST: combination of EX and rST
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: rST: reduce ST and increase nonexercise physical activity
Number of subjects: 57

Group type: COMPARATOR
Intervention: CON: maintain behavior
Number of subjects: 57
Study: 23176350

Group type: EXPERIMENTAL
Intervention: Acupuncture at local and distal points for 4 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 112
Study: 19236979

Group type: EXPERIMENTAL
Intervention: Balance training complemented with eye movement and visual awareness exercises
Number of subjects: 19

Group type: COMPARATOR
Intervention: Balance training alone
Number of subjects: 19
Study: 17321428

Group type: EXPERIMENTAL
Intervention: Olweus Bullying Prevention Program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 15350231

Group type: EXPERIMENTAL
Intervention: Home-based self-help package (the Heart Manual) alongside standard hospital-based cardiac rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 12066648

Group type: EXPERIMENTAL
Intervention: Amalgam (Dispersalloy)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bonded amalgam (AmalgamBond Plus adhesive system with high‐performance additive powder and Dispersalloy amalgam)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bonded resin composite (Scotchbond Multi‐Purpose adhesive system and Z100 resin composite)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No support (control group)
Number of subjects: 16
Study: 10326065

Group type: EXPERIMENTAL
Intervention: Direct disclosure of BMD results to women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (disclosure through GPs)
Number of subjects: 0
Study: 7661161

Group type: EXPERIMENTAL
Intervention: Triple therapy: bismuth nitrate (4 x 375 mg) plus metronidazole (4 x 250 mg) and tetracycline (4 x 500 mg) daily for 2 wk and ranitidine (150 mg) for the first week and bismuth nitrate (4 x 375 mg) alone for a further 2 wk
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Omeprazole (2 x 40 mg) plus amoxycillin (4 x 500 mg) for 2 wk
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) plus amoxycillin (4 x 500 mg) and tinidazole (2 x 500 mg) for 2 wk
Number of subjects: 144
Study: 2596423

Group type: EXPERIMENTAL
Intervention: Daily alternating slimming diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous slimming diet
Number of subjects: 27
Study: 87551

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 99
Study: 31099946

Group type: EXPERIMENTAL
Intervention: Control‐IQ AP system
Number of subjects: 48

Group type: COMPARATOR
Intervention: RM‐SAP
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Control‐IQ AP system and RM‐SAP
Number of subjects: 48
Study: 28741578

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1830
Study: 25039582

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 97
Study: 23656173

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60‐min period for 5 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (Group B, same dosage and administration of normal saline as Group A)
Number of subjects: 32
Study: 22248833

Group type: EXPERIMENTAL
Intervention: H5N1-AS03(A) adjuvanted formulations
Number of subjects: 400

Group type: COMPARATOR
Intervention: H5N1-DIL nonadjuvanted formulations
Number of subjects: 400
Study: 19193660

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (1.6 g/meal) rich in n‐3 alpha‐linolenic acid (ALA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Commercial complementary meals with corn oil (3.4 g/meal) rich in n‐6 linoleic acid (LA)
Number of subjects: 102
Study: 17329271

Group type: EXPERIMENTAL
Intervention: Flomoxef sodium for 2 days (89 patients)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Flomoxef sodium for 5 days (91 patients)
Number of subjects: 180
Study: 16527713

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LAVH in overweight patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: TLH in overweight patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LAVH in obese patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: TLH in obese patients
Number of subjects: 72
Study: 14738260

Group type: EXPERIMENTAL
Intervention: Intravenous anti-D
Number of subjects: 23

Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 23
Study: 10591382

Group type: EXPERIMENTAL
Intervention: 9 mg of intra-arterial recombinant prourokinase (r-proUK) plus heparin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Heparin only (control)
Number of subjects: 180
Study: 8708717

Group type: EXPERIMENTAL
Intervention: High-dose leucovorin (FA) 500 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group A)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Low-dose leucovorin (FA) 20 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group B)
Number of subjects: 291
Study: 1788750

Group type: EXPERIMENTAL
Intervention: Intravenous PGE1 (60 mcg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study: 6267643

Group type: COMPARATOR
Intervention: 8 mg of naloxone IV
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 mg of naloxone
Number of subjects: 14
Study: 30932998

Group type: EXPERIMENTAL
Intervention: New-onset exudation detected in 92 eyes; 1 month before conversion, hyperreflective foci, pigment epithelial detachment, retinal pigment epithelial defects, and haze were present in the majority of eyes.
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: At the onset of exudation
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: 1 month before conversion
Number of subjects: 1097
Study: 30280459

Group type: EXPERIMENTAL
Intervention: 100 μg selenium/day as selenium-enriched yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 200 μg selenium/day as selenium-enriched yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 300 μg selenium/day as selenium-enriched yeast
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo (placebo-yeast)
Number of subjects: 491
Study: 27545511

Group type: EXPERIMENTAL
Intervention: Ibuprofen IR/ER 600 mg (formulation A)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Ibuprofen IR/ER 600 mg (formulation B)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 25599304

Group type: EXPERIMENTAL
Intervention: Intrathecal ketorolac
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 23974250

Group type: EXPERIMENTAL
Intervention: Diabetic foot group (n=57)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Diabetes group (n=49)
Number of subjects: 137
Study: 20960019

Group type: EXPERIMENTAL
Intervention: TEP (laparoscopic totally extraperitoneal)
Number of subjects: 128

Group type: COMPARATOR
Intervention: LICHT (open tension‐free mesh repair)
Number of subjects: 128